News

Advanced Micro Devices (NASDAQ:AMD) is having one of those years where two opposite descriptions of the stock are both accurate. Shares trade near $465 as of this writing. That is more than triple

You can buy Space Exploration Technologies (NASDAQ: SPCX) on the Nasdaq, but the vast majority of shares are still locked up. On June 12, the company sold 639 million shares at its initial public

Vertex Pharmaceuticals (NASDAQ: VRTX) has dominated the cystic fibrosis (CF) drug market -- where it has a virtual monopoly -- since it launched its first medicine in this field in 2012. As a

The market values Broadcom (NASDAQ: AVGO), Advanced Micro Devices (NASDAQ: AMD), and Nvidia (NASDAQ: NVDA) differently because it sees them playing distinct roles in the AI stack. The single metric

As a former top lieutenant to George Soros, Stanley Druckenmiller has built a reputation for delivering big long-term returns through disciplined macro analysis. His primary investment vehicle today

During his three decades as manager of the hedge fund Duquesne Capital, Stanley Druckenmiller averaged annual returns of around 30%, beating not just the S&P 500 but also many other major hedge

President & COO Nnamdi Njoku reported a sale of 6,753 shares of Omnicell, Inc. (NASDAQ:OMCL) at ~$37.09 per share on August 15, 2026, and August 17, 2026, according to a SEC Form 4 filing.

The Dow Jones Industrial Average (DJINDICES:^DJI) rose 0.22% to 53,463, the S&P 500 (SNPINDEX:^GSPC) gained 0.21% to 7,708, and the Nasdaq Composite (NASDAQINDEX:^IXIC) edged 0.16% higher to 26,331

A late-stage trial that combined a messenger ribonucleic acid (mRNA) shot jointly developed by Moderna (NASDAQ:MRNA) and Merck with Merck’s Keytruda yielded strong results in what's being viewed as

Dividend growth stocks can be attractive long-term buys, as the income they provide is likely to rise over time. But many stocks that have long streaks don't often raise their payouts at high rates

Harvard University's endowment, known as Harvard Management, just disclosed a $2.2 billion investment in Space Exploration Technologies (NASDAQ: SPCX) , commonly known as SpaceX.

Harvard's

Billionaire hedge fund manager Ken Griffin was in the news after he scooped up most of the public stock portfolio formerly held by Situational Awareness late last month. In what was otherwise a bad

New investors who are just starting out and building up their portfolios might feel overwhelmed with what to invest in these days. Many stocks are soaring due to artificial intelligence and other

Sandisk (NASDAQ: SNDK) has been by far the best-performing S&P 500 (SNPINDEX: ^GSPC) stock in 2026 with a 544% year to date gain as of the market close on Aug. 13. Sandisk is followed by Dell

Broader equities have been volatile this year, and there is no telling what may come next. Perhaps geopolitical tensions, inflation, and other macroeconomic factors will intensify, leading to a bear

Advanced Micro Devices (NASDAQ:AMD) primarily generates revenue by designing, developing, and selling advanced microprocessors, discrete graphics processing units, and highly customized

The Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD) is one of the market's most popular dividend-focused exchange-traded funds (ETFs). It passively tracks the Dow Jones U.S. Dividend 100 Index, and

The GLP-1 market may be one of the fastest-growing in the pharmaceutical industry right now. Many of the largest drugmakers are looking to capitalize on this and are developing promising GLP-1

For years, AbbVie (NYSE: ABBV) was known primarily for immunology. Humira built the company into a pharmaceutical giant, and newer blockbusters Skyrizi and Rinvoq have helped replace much of the

Demand for GLP-1 drugs is exploding. While medicines in this category traditionally treated diabetes, they are now being approved to manage other conditions, including obesity and obstructive sleep

The past couple of years have been volatile for Vertex Pharmaceuticals (NASDAQ: VRTX). Between clinical setbacks and worse-than-expected financial results, the company has sometimes disappointed

Choosing between AbbVie (NYSE:ABBV) and Bristol-Myers Squibb (NYSE:BMY) requires weighing high-growth immunology assets against deep value as both drugmakers navigate a shifting landscape of patent